Overview

Novartis’ Zolgensma or Biogen’s Spinraza: Which will be the standard of care for spinal muscular atrophy? Novartis shared its perspective with Scrip. Find out what Biogen had to say about the competition during an earnings call and how Novaratis’ Paul Hudson responded. Learn why he thinks Zolgensma will become the standard of care. Find out how Novartis plans to handle payment for the costly therapy. Is it considering outcomes-based payments? If so, where? Gain insights into the clinical benefits of both medications and learn what’s next.